Multicenter Study Differentiated Thyroid Carcinoma
Launched by UNIVERSITY HOSPITAL MUENSTER · Sep 1, 2005
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
MSDS was designed as a comprehensive cohort trial with randomization and observation arms. Patients are enrolled at the time of the first ablative radioiodine therapy (RIT). Inclusion criteria are papillary or follicular DTC pT4 pN0/1/x M0/x, age between 18 (incl.) and 70 years (excl.) at the time of initial surgery, completion of primary surgical therapy with R0 (no tumor residues) or R1 (microscopic residues) resection, Karnofsky index of at least 70 %, freedom from distant metastases at the time of initial radioiodine therapy (RIT), and informed patient consent. Criteria for exclusion ar...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • papillary or follicular thyroid carcinoma pT4 pN0/1/x M0/x
- • completion of primary surgical therapy with R0 (no tumor residues) or R1 (microscopic residues) resection
- • Karnofsky index \> 70 %
- • freedom from distant metastases at the time of initial radioiodine therapy
- • informed patient consent
- Exclusion Criteria:
- • secondary malignancy except basalioma
- • pregnancy
- • serious general disease
- • serious psychiatric disorder
- • inability to give informed consent
- • previous RTx
- • recurrence of previous thyroid cancer
About University Hospital Muenster
University Hospital Münster is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and developing new therapeutic strategies. With a strong focus on collaboration and ethical research practices, University Hospital Münster plays a pivotal role in translating scientific discoveries into practical applications, fostering a culture of inquiry that benefits both the medical community and the patients it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Linz, , Austria
Wien, , Austria
Halle, , Germany
Homburg/Saar, , Germany
Köln, , Germany
Münster, , Germany
Stuttgart, , Germany
Wuppertal, , Germany
Würzburg, , Germany
Zürich, , Switzerland
Patients applied
Trial Officials
Otmar Schober, Prof MD PhD
Study Chair
Department of Nuclear Medicine, Münster University Hospital, Münster, Germany
Henning Dralle, Prof MD
Study Director
Dept. of General Surgery, University Halle-Wittenberg, Halle, Germany
Normann Willich, Prof MD
Study Director
Department of Radiooncology, Münster University Hospital, Münster, Germany
Martin Biermann, MD
Study Director
Dept. of Nuclear Medicine, Münster University Hospital
Burkhard Riemann, MD PhD
Study Director
Dept. of Nuclear Medicine, Münster University Hospital
Andreas Schuck, MD PhD
Study Director
Dept. of Radiooncology, Münster University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials